Lucid Diagnostics Inc.
LUCD
$-0.02
Change (1 day)
$1.58
Year High
$0.63
Year Low
Categories
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. (LUCD) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 45 K | -3,641,000 | 29.58 M | 27.27 M | 22.07 M |
| 2022 | 17 K | -20,475,000 | 9.46 M | 32.51 M | 24.36 M |
| 2021 | 200 K | -53,656,000 | 4.26 M | 59 M | 57.3 M |
| 2020 | 1 | -111,255 | 15.71 M | 2.19 M | 1.44 M |
| 2019 | -156,404 | 6.34 M | 1.03 M | 390.9 K |